Literature DB >> 7092360

A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

C W Olanow, A S Wechsler, A D Roses.   

Abstract

Forty-seven consecutively presenting myasthenia gravis (MG) patients with generalized weakness were treated according to a standardized prospective protocol. All patients underwent a sternal splitting "total" thymectomy. Medical status before surgery was optimized by plasmapheresis without immunosuppression. Medications were avoided or discontinued whenever possible. All patients were improved. At the time of latest follow-up 83% were free of generalized weakness and 61% were on no medications. There was no significant change in Acetylcholine Receptor Antibody (AChR-AB) titer. The following conclusions were made: (1) thymectomy is an effective therapy for MG, (2) additional medications are not necessary in the majority of patients, and (3) a reduction in the AChR-AB titer is not essential for clinical benefit.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092360      PMCID: PMC1352464          DOI: 10.1097/00000658-198208000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  40 in total

1.  Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations.

Authors:  G Genkins; A E Papatestas; S H Horowitz; P Kornfield
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

2.  Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure.

Authors:  A G Engel; E H Lambert; T Santa
Journal:  Neurology       Date:  1973-12       Impact factor: 9.910

3.  Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

Authors:  R R Almon; C G Andrew; S H Appel
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

4.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

5.  Effect of thymectomy in patients with myasthenia gravis. A sixteen year experience.

Authors:  D G Mulder; C Herrmann; G D Buckberg
Journal:  Am J Surg       Date:  1974-08       Impact factor: 2.565

6.  Autoimmune response to acetylcholine receptor.

Authors:  J Patrick; J Lindstrom
Journal:  Science       Date:  1973-05-25       Impact factor: 47.728

7.  The role of thymectomy in the treatment of myasthenia gravis.

Authors:  V P Perlo; B Arnason; D Poskanzer; B Castleman; R S Schwab; K E Osserman; A Papatestis; L Alpert; A Kark
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

Review 8.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

9.  Experimental autoimmune myasthenia gravis: cellular and humoral immune responses.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

10.  Evaluation of results of thymectomy in myasthenia gravis.

Authors:  B Emeryk; M H Strugalska
Journal:  J Neurol       Date:  1976-01-14       Impact factor: 4.849

View more
  19 in total

Review 1.  Molecular mimicry--hypothesis or reality?

Authors:  N Tsuchiya; R C Williams
Journal:  West J Med       Date:  1992-08

2.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

3.  Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients.

Authors:  A Melms; B C Schalke; T Kirchner; H K Müller-Hermelink; E Albert; H Wekerle
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

4.  [Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy].

Authors:  F Schumm; A Fateh-Moghadam; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

5.  Myasthenia gravis. Pathogenesis and current concepts in management.

Authors:  C W Havard; G K Scadding
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 6.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

7.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12

8.  Videothoracoscopic thymectomy for nonthymomatous myasthenia gravis: results of 90 patients.

Authors:  Alper Toker; Serhan Tanju; Zerrin Sungur; Yesim Parman; Mert Senturk; Piraye Serdaroglu; Sukru Dilege; Feza Deymeer
Journal:  Surg Endosc       Date:  2007-08-18       Impact factor: 4.584

9.  Thymectomy for myasthenia gravis: 14-year experience.

Authors:  J R Hankins; R F Mayer; J R Satterfield; S Z Turney; S Attar; A J Sequeira; B W Thompson; J S McLaughlin
Journal:  Ann Surg       Date:  1985-05       Impact factor: 12.969

Review 10.  Unraveling the role of ectopic thymic tissue in patients undergoing thymectomy for myasthenia gravis.

Authors:  Feng Li; Ya Tao; Gero Bauer; Aron Elsner; Zhongmin Li; Marc Swierzy; Julianna Englisch; Andreas Meisel; Mahmoud Ismail; Jens-C Rückert
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.